Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacticaseibacillus rhamnosus GG for Allergic Rhinoconjunctivitis
NCT04898686Completed
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of Lactobacillus rhamnosus GG in allergic rhinoconjunctivitis (ARC) (2 arms). Primary endpoints: Transfer of L. rhamnosus GG to the oronasopharyngeal cavity at 8 weeks and Changes in the score of allergic rhinitis symptoms at 10 weeks. Started Aug 2020; status: completed.
02
Drugs
Lactobacillus rhamnosus GG
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT04898686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898686.